News

Clinical Trials for Psilocybin Indicate No Adverse Effects

Clinical Trials for Psilocybin Indicate No Adverse Effects

A phase I clinical trial conducted by researchers at King's College London and mental healthcare company Compass Pathways, indicates that the drug psilocybin has no adverse effects. Psilocybin induces hallucinogenic symptoms, which may be advantageous for some suffering from chronic depression. Yourway is able to transport even controlled substances across our global network.

Back to Index
Media

Upcoming Event

IQPC CTS

August 24-26, 2020
Brussels, Belgium

Media

Articles

The New Normal in Clinical Trial Protection

Open chat
Come chat with us!
Hello! How can I help you?